Novel Treatment Options for Multiple Myeloma – Enduring Webcast

Description

Program Description

---

This webcast is intended to improve care of patients with multiple myeloma by accelerating adoption of new guidelines and evidence-based practice change. One of the most important advances in the field has been the appreciation of the genetic heterogeneity that underlies this disease and its impact on MM’s patients’ outcomes. These newly identified genetic abnormalities and previously described prognostic factors have opened the possibility of prospective risk stratification of patients with MM and subsequent tailoring of therapy individually. In the era of modern MM therapy, the prognostic significance of MRD negativity is independent of the treatment received or cytogenetic high-risk status.

Intended Audience

---

This webcast is designed to meet the educational needs of community-based hematologists/ oncologists, nurse practitioners, physician assistants, and nurses involved in diagnosing and treating patients with newly diagnosed multiple myeloma (NDMM) and relapsed and refractory multiple myeloma (RRMM).

Commercial Supporter

---

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.